P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib TherapyHelena A. Yu, Jonathan W. Riess, Xiuning Le et al.|Journal of Thoracic Oncology|2019Cited by 26